Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cryotherapy Combined With Intralesional HBV Vaccine for Multiple Cutaneous Warts
NCT05902624Phase 1Not yet recruiting
- Sponsor
- Assiut University
- Start
- Aug 2024
- Primary completion
- May 2025
- Modality
- Vaccines & Immunotherapeutics
01
Overview
Phase 1, randomised, open-label trial of hepatitis b vaccine in cutaneous warts (3 arms), sponsored by Assiut University. Primary endpoints: Efficacy of combined cryotherapy with intralesional HBV vaccine injection at 10 weeks and Safety of combined cryotherapy with intralesional HBV vaccine injection at 10 weeks. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
hepatitis b vaccine
03
Conditions
cutaneous warts
Beyond the preview
Go deeper on NCT05902624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05902624.